Pradefovir mesylate

CAS : 625095-61-6

Ref. 3D-AAB09561

Informations sur le produit

• Nom: Pradefovir mesylate
• Synonymes: 9-(2-{[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphinan-2-yl]methoxy}ethyl)-9H-purin-6-amine methanesulfonate (1:1), 9H-Purin-6-amine, 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]ethyl]-, methanesulfonate (1:1), 9H-Purin-6-amine, 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]ethyl]-, monomethanesulfonate, Hepavir B, MB-06866，MB-6866，Hepavir B，Remofovir mesylate, Mb 06866Q, Pradefovir Mesilate, Remofovir mesylate

Description

Pradefovir mesylate is a prodrug that is converted to pradefovir in the human body. It has been shown to be an effective antiviral drug for the treatment of HIV infection and hepatitis B virus. Pradefovir prevents replication of the virus by blocking reverse transcriptase, which is required for viral DNA synthesis. In vitro studies have found that it also inhibits other members of the hepadnavirus family, such as hepatitis C and D, through its action on reverse transcriptase. This drug has a low toxicity profile in animal studies and can be given orally or intravenously. The drug's matrix effect may cause it to accumulate in regions of high fat content, such as the liver and spleen, although this property may also help it penetrate areas where viruses replicate, such as CD4+ cells.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 519.9 g/mol
• Formule: C₁₈H₂₃ClN₅O₇PS
• Degré de pureté: Min. 95%